Librarian View
LEADER
05500nam a22005415i 4500
001
16568288
005
20230222161719.0
006
m o d
007
cr nn 008mamaa
008
230207s2023 si | o |||| 0|eng d
020
|a
9789811953996
024
7
|a
10.1007/978-981-19-5399-6
|2
doi
035
|a
(DE-He213)978-981-19-5399-6
050
4
|a
RC1-1245
245
1
0
|a
Drug Repurposing for Emerging Infectious Diseases and Cancer
|h
[electronic resource] /
|c
edited by Ranbir Chander Sobti, Sunil K. Lal, Ramesh K. Goyal.
250
|a
1st ed. 2023.
264
1
|a
Singapore :
|b
Springer Nature Singapore :
|b
Imprint: Springer,
|c
2023.
300
|a
1 online resource (XXI, 654 p.) 1 illus.
336
|a
text
|b
txt
|2
rdacontent
337
|a
computer
|b
c
|2
rdamedia
338
|a
online resource
|b
cr
|2
rdacarrier
347
|a
text file
|b
PDF
|2
rda
505
0
|a
Chapter 1. Drug repurposing: an advance way to traditional drug discovery -- Chapter 2. Drug polypharmacology towards drug repurposing -- Chapter 3. Pharmacovigilance based drug repurposing -- Chapter 4. In silico analysis of cellular interactors of pqbp1 for potential drug repurposing -- Chapter 5. Drug repurposing opportunities in cancer -- Chapter 6. Repurposing of flavonoids as promising phytochemicals for the treatment of lung carcinoma -- Chapter 7. Targeted therapies used in the treatment of non-small cell lung cancer: an overvie -- Chapter 8. Targeting the ubiquitin machinery for cancer therapeutics -- Chapter 9. Repurposing of serotonin pathway influencing drugs for potential cancer therapy and antimicrobial functions -- Chapter 10. Drug repurposing for hematological malignancies -- Chapter 11. Drug repurposing for ent and head and neck infectious and oncologic diseases: current practices and future possibilities -- Chapter 12. Repurposing of immun-modulators for the treatment of cancer with qsar approaches -- Chapter 13. Reverse translational approach in repurposing of drugs for anticancer therapy -- Chapter 14. Therapeutic targeting of antineoplastic drugs in alzheimer's disease: discovered in repurposed agents -- Chapter 15. Repurposing of drugs for the treatment of microbial diseases -- Chapter 16. Repurposing anti-inflammatory agents in the potential treatment of sars-cov-2 infection -- Chapter 17. Repurposing drugs for viruses and cancer: a novel drug repositioning strategy for covid-19 -- Chapter 18. Repurposing of serotonin pathway influencing drugs for potential cancer therapy and antimicrobial functions -- Chapter 19. Drug repurposing for covid-19 therapy: pipeline, current status and challenges -- chapter 20. Deoxy-d-glucose - a repurposed drug for covid-19 treatment -- Chapter 21. Repurposing methylene blue for the management of covid-19: prospects, paradox and perspective -- Chapter 22. Drug repurposing in covid-19 and cancer: how far have we come? -- Chapter 23. Repurposing of doxycycline to attenuate influenza virus pathogenesis via inhibition of matrix metalloproteinases in neutrophils -- Chapter 24. Therapeutic repurposing approach: new opportunity for developing drugs against covid‑19 -- chapter 25. Repurposing drugs for viruses and cancer: a novel drug repositioning strategy for covid-19 -- Chapter 26. Repurposing of therapeutic approaches for the treatment of vitiligo -- Chapter 27. Emerging infections and their management -- Chapter 28. Repurposing of minocycline, a tetracycline antibiotic, for neurodegenerative disorders.
506
|a
Access restricted by licensing agreement.
520
|a
This book presents drug repurposing strategies to combat infectious diseases and cancer. It discusses key experimental and in silico approaches for modern drug repositioning, including signature matching, molecular docking, genome-wide associated studies, and network-based approaches aided by artificial intelligence. Further, the book presents various computational and experimental strategies for better understanding disease mechanisms and identify repurposed drug candidates for personalized pharmacotherapy. It also explores the databases for drug repositioning, summarizes the approaches taken for drug repositioning, and highlights and compares their characteristics and challenges. Towards the end, the book discusses challenges and limitations encountered in computational drug repositioning.
590
|a
Access is available to the Yale community.
650
0
|a
Diseases.
650
0
|a
Therapeutics.
650
0
|a
Pharmacology.
650
0
|a
Oncology.
700
1
|a
Sobti, Ranbir Chander.
|e
editor.
|4
edt
|4
http://id.loc.gov/vocabulary/relators/edt
700
1
|a
Lal, Sunil K.
|e
editor.
|4
edt
|4
http://id.loc.gov/vocabulary/relators/edt
700
1
|a
Goyal, Ramesh K.
|e
editor.
|4
edt
|4
http://id.loc.gov/vocabulary/relators/edt
710
2
|a
SpringerLink (Online service)
730
0
|a
Springer ENIN.
773
0
|t
Springer Nature eBook
776
0
8
|i
Printed edition:
|z
9789811953989
776
0
8
|i
Printed edition:
|z
9789811954009
776
0
8
|i
Printed edition:
|z
9789811954016
852
8
0
|b
yulintx
|h
None
|z
Online resource
852
8
0
|z
Online resource
856
4
0
|y
Online book
|u
https://yale.idm.oclc.org/login?URL=https://doi.org/10.1007/978-981-19-5399-6
901
|a
RC1-1245
902
|a
Yale Internet Resource
|b
Yale Internet Resource >> None|DELIM|16475729
905
|a
online resource
907
|a
2023-02-22T16:17:19.000Z
946
|a
DO NOT EDIT. DO NOT EXPORT.
953
|a
https://doi.org/10.1007/978-981-19-5399-6